Australia markets close in 5 hours 56 minutes

Context Therapeutics Inc. (CNTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.2500+0.0300 (+1.35%)
At close: 04:00PM EDT
2.2200 -0.03 (-1.33%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.2200
Open2.2100
Bid2.2200 x 1000
Ask2.2300 x 900
Day's range2.2100 - 2.3750
52-week range1.2700 - 10.8700
Volume316,642
Avg. volume415,995
Market cap35.924M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.9300
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Deliver On Growth Plans?

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • GlobeNewswire

    Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results

    Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting Preclinical data presented at AACR Annual Meeting showcased potential of ONA-XR and CLDN6xCD3 bispecific development program PHILADELPHIA, May 11, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treat

  • GlobeNewswire

    Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting

    Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates monotherapy clinical activity in advanced granulosa cell tumor of the ovary Trial advanced to second stage to evaluate combination of ONA-XR with oral antiestrogen PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced